Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg

Phase 3 Completed 1613 enrolled Novartis

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to investigate the efficacy, safety and tolerability of aliskiren 300 mg, 150 mg and 75 mg when compared to ramipril 5 mg in patients with essential hypertension.

Timeline

Start: 2007-09
Primary completion: 2008-07
Completion: 2008-07

Publications

Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD012569. doi: 10.1002/14651858.CD012569.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aliskiren	Small molecule	75 mg	—
Subject	Aliskiren	Small molecule	150 mg	—
Subject	Aliskiren	Small molecule	300 mg	—
Comparator	Ramipril	Small molecule	5 mg	—

Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg

Summary

Timeline

Publications

Drugs

Indications